Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | EIF4A3 | P38919 | 11/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.55 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11958707 | 0.94 | LMNA (0.54) | ALDH1A1LMNAEIF4A3MDM2SMO | |
| SCHEMBL11958225 | 0.84 | ALDH1A1 (0.53) | ALDH1A1LMNAEIF4A3MDM2SMO | |
| SCHEMBL11957713 | 0.84 | MDM2 (0.55) | ALDH1A1LMNAEIF4A3MDM2SMO | |
| SCHEMBL11957725 | 0.84 | MDM2 (0.53) | ALDH1A1LMNAEIF4A3MDM2MGLL | |
| SCHEMBL15165926 | 0.83 | MDM2 (0.45) | ALDH1A1LMNAEIF4A3MDM2SMO | |
| SCHEMBL11980246 | 0.81 | GFER (0.55) | ALDH1A1MDM2MEN1KMT2A | |
| SCHEMBL11958336 | 0.81 | CNR1 (0.47) | EIF4A3MDM2 | |
| SCHEMBL11958708 | 0.79 | LMNA (0.51) | LMNAEIF4A3MDM2MGLLMEN1 | |
| SCHEMBL11958798 | 0.79 | LMNA (0.47) | ALDH1A1LMNAMDM2SMO | |
| SCHEMBL11957955 | 0.79 | EIF4A3 (0.53) | EIF4A3MDM2SMOMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | ALDH1A1 1520/4885LMNA 4038/4885EIF4A3 3965/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | ALDH1A1 1520/4885LMNA 4038/4885EIF4A3 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.